Sphera Funds Management’s BridgeBio Pharma BBIO Stock Holding History

Sphera Funds Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.2M	Buy	245,246 +137,500	+128%	+$9.97M	2.89%	6
2025 Q4	$8.24M	Buy	107,746 +67,000	+164%	+$4.4M	1.59%	16
2025 Q3	$2.12M	Sell	40,746 -46,362	-53%	-$2.26M	0.45%	72
2025 Q2	$3.76M	Sell	87,108 -279,500	-76%	-$10.2M	0.88%	42
2025 Q1	$12.7M	Sell	366,608 -538,671	-60%	-$18.2M	2.92%	7
2024 Q4	$24.8M	Buy	905,279 +62,635	+7%	+$1.62M	4.49%	2
2024 Q3	$21.5M	Sell	842,644 -67,426	-7%	-$1.77M	3.41%	3
2024 Q2	$23.1M	Buy	910,070 +324,114	+55%	+$8.86M	3.14%	3
2024 Q1	$18.1M	Buy	585,956 +303,810	+108%	+$10.3M	2.55%	8
2023 Q4	$11.4M	Sell	282,146 -63,391	-18%	-$1.9M	1.83%	16
2023 Q3	$9.11M	Buy	345,537 +23,902	+7%	+$678K	1.66%	14
2023 Q2	$5.53M	Sell	321,635 -240,348	-43%	-$3.62M	0.86%	46
2023 Q1	$9.32M	Buy	+561,983	New	+$6.55M	1.56%	19
2021 Q2	–	Sell	-23,890	Closed	-$1.47M	–	136
2021 Q1	$1.47M	Sell	23,890 -134,010	-85%	-$8.77M	0.11%	131
2020 Q4	$11.2M	Buy	+157,900	New	+$7.62M	1%	27

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's BBIO Position: Q1 2026 in Review

Sphera Funds Management increased its BridgeBio Pharma (BBIO) stake by 128% in Q1 2026, buying an estimated $9.97M and bringing the position to 245,246 shares worth $18.2M. The position accounts for 2.89% of the portfolio, ranked #6.

Sphera Funds Management first reported a position in BBIO in Q4 2020 and has held it in 15 quarters since. The position peaked at $24.8M in Q4 2024. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Sphera Funds Management held 245,246 shares of BridgeBio Pharma worth $18.2M as of Q1 2026.
Sphera Funds Management bought 137,500 BridgeBio Pharma shares in Q1 2026, an estimated $9.97M.
BridgeBio Pharma made up 2.89% of Sphera Funds Management's portfolio in Q1 2026, its #6 holding.
Sphera Funds Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 15 quarters since.
Sphera Funds Management's BridgeBio Pharma position peaked at $24.8M in Q4 2024.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.